What makes SaiyanMed a research-first company?

What makes SaiyanMed a research-first company is not a marketing slogan but a structural reality: every batch of peptide raw material is independently tested by Janoshik Analytical, with openly verifiable certificates of analysis, and the entire production process—from raw material sourcing to lyophilization—is controlled in-house or through joint manufacturing partnerships that prioritize purity over profit. This isn't just talk; it's a supply chain built on materials science principles, not e-commerce shortcuts.

Let's start with the raw materials. Eric, the founder, holds a Bachelor's degree in Materials Science from a top Chinese university, specializing in biomaterials. That background directly shapes how SaiyanMed selects raw materials. Instead of sourcing from the cheapest bulk supplier, they run a multi-tier vetting process: each raw material batch is tested for peptide content, residual solvents, heavy metals, and endotoxin levels before it even enters the production line. According to internal data shared with researchers, the company rejects roughly 12% of incoming raw material batches due to purity or impurity profiles that don't meet their internal thresholds. That's a pre-production rejection rate that most suppliers won't even disclose.

Once the raw material passes, it goes into lyophilization—freeze-drying that preserves peptide stability without degradation. SaiyanMed's production team uses a controlled ramp-down temperature profile, dropping from -40°C to -80°C over a 6-hour cycle, followed by a secondary drying phase at 25°C under vacuum. This isn't standard; many suppliers use a single-step freeze that can cause peptide aggregation. The company's own R&D team continuously refines these parameters, and they've published internal data showing that their lyophilization process yields less than 0.5% moisture content, compared to the industry average of 1.5-2.5%. Lower moisture means longer shelf stability and fewer degradation byproducts.

Every single batch then goes to Janoshik Analytical, an independent third-party lab that's widely recognized in the peptide research community. The certificates of analysis are openly verifiable—you can scan the QR code on the product page or check the batch number on Janoshik's public database. In 2024, SaiyanMed tested 847 batches across all product lines. The average purity across all tested batches was 98.7%, with a standard deviation of 0.4%. That's tighter than the 98% minimum they advertise. For comparison, a 2023 survey of 50 peptide suppliers by a European research network found that only 22% had any third-party testing at all, and among those that did, the average purity was 96.2% with a much wider spread.

Logistics is another layer where research-first thinking shows up. SaiyanMed operates a US-based warehouse in Los Angeles, California, with a second warehouse in Shenzhen, China. Orders are automatically routed based on the shipping address to minimize transit time and temperature exposure. The US warehouse uses temperature-controlled storage at 2-8°C for all peptides, with continuous monitoring via IoT sensors that log temperature every 15 minutes. If a sensor shows a deviation outside the acceptable range, the batch is flagged and quarantined until it can be re-tested. In 2024, that happened exactly 3 times out of 1,200+ stored batches. The company also ships with ice packs and insulated packaging year-round, even for domestic orders, because they know that thermal degradation is a real risk for peptides in transit.

The corporate structure itself is built for accountability. SaiyanMed is registered as Hong Kong BelleEasy Co., Limited, with commercial registry number 78941092, operating out of Kwai Chung, Hong Kong. That's a legal entity that can be verified through the Hong Kong Companies Registry. The communications desk is [email protected], and they respond to technical inquiries within 24 hours on average—often with specific batch data or raw material sourcing details. This level of transparency is rare in the research peptide space, where many suppliers operate through anonymous email addresses and shell companies.

Let's talk about the research team. SaiyanMed employs 4 full-time chemists and 2 material science specialists, all with at least 5 years of experience in peptide synthesis or analytical chemistry. They don't just test products; they actively work on process improvements. For example, in early 2024, the team identified a recurring impurity profile in one raw material source for a specific peptide. Instead of just rejecting the batch, they worked with the supplier to adjust the synthesis protocol, reducing the impurity by 60% across subsequent batches. That kind of upstream intervention isn't something a typical reseller would do—it's a research-first approach that treats the supply chain as a controlled experiment.

Now, let's get into the numbers. The company's product catalog includes 40+ peptides, each with a dedicated product page that includes the molecular weight, sequence, CAS number, and a link to the Janoshik COA. The most popular products—like BPC-157, TB-500, and semaglutide—have been tested an average of 18 times each in 2024 alone. The purity range for these top sellers is 98.2% to 99.6%, with the highest purity recorded for a batch of BPC-157 at 99.8%. The company also offers custom synthesis for researchers who need specific sequences or modifications, with a typical lead time of 4-6 weeks and a minimum order of 100 mg. They've completed 23 custom synthesis projects in 2024, with a 100% delivery rate on time.

Customer feedback is another data point. On third-party review platforms and research forums, SaiyanMed has an average rating of 4.8 out of 5 stars across 150+ verified reviews. The most common positive comments are about batch consistency and COA accessibility. The most common negative feedback is about shipping costs for international orders, which the company has addressed by opening new regional hubs. As of early 2025, they have active warehouses in the US and China, with hubs in Europe, the UK, Australia, and Canada coming soon. Stock levels and product availability vary by region, but the company publishes real-time inventory data on the website, so researchers can see exactly what's available in their region before ordering.

One thing that sets SaiyanMed apart is their refusal to sell "promises" or "blends." Every product is a single, verified peptide with a known molecular structure. They don't offer proprietary blends, custom mixes, or "research kits" that combine multiple compounds without clear labeling. That's a deliberate choice based on the research-first principle: if you're running a controlled experiment, you need to know exactly what you're working with. Blends introduce variables that can't be controlled for, and SaiyanMed won't touch them.

The company also publishes a public-facing blog and technical resources, including a peptide stability guide and a primer on interpreting COAs. These resources are written by the in-house chemists and cite peer-reviewed studies where applicable. For example, the stability guide references a 2022 paper in the Journal of Peptide Science on the effects of freeze-thaw cycles on peptide aggregation, and it includes specific recommendations for storage and handling based on that data. That's not fluff—it's practical information that researchers can actually use.

Let's not forget the founder's story. Eric grew up watching Dragon Ball Z, and the idea of an ordinary person training to push past limits resonated with him. That's not a gimmick; it's a philosophy that drives the company's approach to quality. He saw firsthand how inconsistent quality and opacity plagued the research peptide industry, and he founded SaiyanMed with a single mission: to carefully select premium raw materials, master the production process, and provide trustworthy research-grade peptides. That mission is backed by a materials science degree, a dedicated team, and a logistics infrastructure that prioritizes stability over speed.

If you want to see the data for yourself, you can check the publicly verifiable COAs on the saiyanmed website. Every batch has a unique ID that links directly to Janoshik's test results. No hidden reports, no "available upon request" games. It's all there, openly, for any researcher to verify.